<style>
/* 背景保持你原来的图，稍微加一点白色柔化 */
body {
  background:
    linear-gradient(rgba(255,255,255,0.55), rgba(255,255,255,0.55)),
    url("car-t-cell-therapy-2x.jpg");
  background-size: cover;
  background-attachment: fixed;
  background-position: center;
  font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", system-ui, sans-serif;
}

/* 外层容器：控制整体宽度和居中 */
.lab-container {
  max-width: 960px;
  margin: 40px auto 60px auto;
}

/* 每个研究方向的一块“白底卡片” */
.lab-section {
  background: rgba(255,255,255,0.90);
  border-radius: 10px;
  padding: 20px 24px;
  margin-bottom: 20px;
  box-shadow: 0 6px 18px rgba(0,0,0,0.08);
  border-left: 4px solid #8c1515; /* Stanford 深红 */
}

/* 标题 */
.lab-section h2 {
  font-size: 22px;
  margin: 0 0 8px 0;
  color: #2c3e50;
  font-weight: 600;
}

/* 正文 */
.lab-section p {
  font-size: 16px;
  line-height: 1.7;
  color: #333333;
  margin: 0;
}
</style>

[Home](/lab) · [Members](/lab/members) · [Projects](/lab/projects) · [Publications](/lab/publications) · [Contact](/lab/contact)

---

<div class="lab-container">

  <div class="lab-section">
    <h2>1. Virus-driven immune remodeling in transplantation and cellular therapies</h2>
    <p>
      We study how CMV, EBV, and other viral exposures reshape immune reconstitution after HSCT, CAR-T therapy, and other advanced cellular treatments. Using longitudinal CyTOF and single-cell sequencing, we map immune trajectories and identify signatures linked to toxicity, relapse, and infection. Computational models integrate viral kinetics with immune dynamics to guide precision monitoring and therapeutic decision-making.
    </p>
  </div>

  <div class="lab-section">
    <h2>2. Precision immunology and immunotherapy in acute myeloid leukemia</h2>
    <p>
      AML serves as a key disease model to understand therapy-induced immune remodeling. We investigate how induction regimens such as HAV, antigen drift, and immune microenvironment in AML patients shape treatment outcomes. We also develop and evaluate AML-directed immunotherapies—including CAR-T cells, vaccines, and viral-antigen–driven immunogenic strategies—to improve antileukemic immunity and long-term survival.
    </p>
  </div>

  <div class="lab-section">
    <h2>3. Integrating HSCT and CAR-T with other immunotherapies to improve treatment outcomes in hematologic malignancies</h2>
    <p>
      We integrate HSCT, CAR-T, and other immune-based strategies to develop multimodal immunotherapeutic approaches aimed at improving long-term disease control in hematologic malignancies.
    </p>
  </div>

</div>
